AUPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AUPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurinia Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | - | - | - | - | - |
Aurinia Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Aurinia Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:
For example, Aurinia Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Sep. 2024 (Change) | * | Current CPI (Sep. 2024) |
= | 0.116 | / | 127.2847 | * | 127.2847 | |
= | 0.116 |
Current CPI (Sep. 2024) = 127.2847.
Aurinia Pharmaceuticals Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201412 | -0.111 | 98.367 | -0.144 |
201503 | -0.127 | 99.789 | -0.162 |
201506 | -0.115 | 100.500 | -0.146 |
201509 | -0.162 | 100.421 | -0.205 |
201512 | -0.148 | 99.947 | -0.188 |
201603 | -0.162 | 101.054 | -0.204 |
201606 | -0.155 | 102.002 | -0.193 |
201609 | -0.116 | 101.765 | -0.145 |
201612 | -0.106 | 101.449 | -0.133 |
201703 | -0.171 | 102.634 | -0.212 |
201706 | -0.169 | 103.029 | -0.209 |
201709 | -0.102 | 103.345 | -0.126 |
201712 | -0.106 | 103.345 | -0.131 |
201803 | -0.171 | 105.004 | -0.207 |
201806 | -0.146 | 105.557 | -0.176 |
201809 | -0.133 | 105.636 | -0.160 |
201812 | -0.160 | 105.399 | -0.193 |
201903 | -0.146 | 106.979 | -0.174 |
201906 | -0.145 | 107.690 | -0.171 |
201909 | -0.128 | 107.611 | -0.151 |
201912 | -0.260 | 107.769 | -0.307 |
202003 | -0.203 | 107.927 | -0.239 |
202006 | -0.202 | 108.401 | -0.237 |
202009 | -0.267 | 108.164 | -0.314 |
202012 | 0.008 | 108.559 | 0.009 |
202103 | -0.430 | 110.298 | -0.496 |
202106 | -0.295 | 111.720 | -0.336 |
202109 | -0.315 | 112.905 | -0.355 |
202112 | -0.197 | 113.774 | -0.220 |
202203 | -0.331 | 117.646 | -0.358 |
202206 | -0.197 | 120.806 | -0.208 |
202209 | -0.109 | 120.648 | -0.115 |
202212 | 0.073 | 120.964 | 0.077 |
202303 | -0.226 | 122.702 | -0.234 |
202306 | -0.021 | 124.203 | -0.022 |
202309 | -0.092 | 125.230 | -0.094 |
202312 | 0.099 | 125.072 | 0.101 |
202403 | -0.129 | 126.258 | -0.130 |
202406 | 0.109 | 127.522 | 0.109 |
202409 | 0.116 | 127.285 | 0.116 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Aurinia Pharmaceuticals (NAS:AUPH) Cyclically Adjusted Price-to-FCF Explanation
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Karen L. Smith | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Jeffrey Allen Bailey | director | BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612 |
Scott Michael Habig | officer: Chief Commercial Officer | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
R. Hector Mackay-dunn | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
Jayne David R.w. | director | #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8 |
Daniel Billen | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8 |
Jill Leversage | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8 |
Brinda Balakrishnan | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
Matthew Maxwell Donley | officer: Ex VP, Intern'l Operations | 4520 EAST WEST HIGHWAY, 3RD FLOOR, BETHESDA MD 20814 |
Stephen P. Robertson | officer: EVP, General Counsel | #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8 |
Joseph M Miller | officer: Chief Financial Officer | C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Peter Greenleaf | director, officer: Chief Executive Officer | ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Volker Knappertz | officer: EVP, Research and Development | SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB249BZ |
Robert T Foster | director | C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837 |
Joseph P Hagan | director | 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037 |
From GuruFocus
By Business Wire • 08-28-2024
By Business Wire • 05-30-2024
By GuruFocus News • 11-07-2024
By Business Wire • 11-18-2024
By Business Wire • 09-05-2024
By Business Wire • 11-07-2024
By Business Wire • 10-30-2024
By GuruFocus Research • 08-01-2024
By GuruFocus News • 11-08-2024
By GuruFocus Research • 08-02-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.